| __timestamp | Amicus Therapeutics, Inc. | Axsome Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 4279200 |
| Thursday, January 1, 2015 | 76943000 | 6776987 |
| Friday, January 1, 2016 | 104793000 | 21199860 |
| Sunday, January 1, 2017 | 149310000 | 19957616 |
| Monday, January 1, 2018 | 270902000 | 23495055 |
| Tuesday, January 1, 2019 | 286378000 | 53647067 |
| Wednesday, January 1, 2020 | 308443000 | 70244579 |
| Friday, January 1, 2021 | 272049000 | 58060725 |
| Saturday, January 1, 2022 | 276677000 | 57947447 |
| Sunday, January 1, 2023 | 152381000 | 97944000 |
| Monday, January 1, 2024 | 187077000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) investments are crucial for driving innovation and growth. Over the past decade, Amicus Therapeutics, Inc. and Axsome Therapeutics, Inc. have demonstrated contrasting strategies in their R&D expenditures.
From 2014 to 2023, Amicus Therapeutics consistently increased its R&D spending, peaking in 2020 with a 547% increase from 2014. This commitment underscores their dedication to advancing therapies for rare diseases.
Axsome Therapeutics, on the other hand, exhibited a more volatile yet aggressive R&D investment strategy. By 2023, their R&D expenses surged by over 2,000% compared to 2014, reflecting their focus on developing novel treatments for central nervous system disorders.
These investment patterns highlight the dynamic nature of the biotech industry, where strategic R&D funding can lead to groundbreaking medical advancements.
R&D Insights: How Teva Pharmaceutical Industries Limited and Amicus Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Genmab A/S vs Axsome Therapeutics, Inc.
Research and Development Expenses Breakdown: Genmab A/S vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Axsome Therapeutics, Inc. and TG Therapeutics, Inc.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and Amicus Therapeutics, Inc.
Viking Therapeutics, Inc. vs Amicus Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs HUTCHMED (China) Limited
Analyzing R&D Budgets: Amicus Therapeutics, Inc. vs Mesoblast Limited